As a dual GIP/GLP-1 receptor agonist, tirzepatide works through two pathways rather than one, which clinical trials have shown produces greater average weight loss compared to semaglutide alone
Youve meticulously planned your research, sourced high-purity compounds, and are ready to begin
#Healthcare #Diabetes #Obesity #Pharma #Innovation To view or add a comment, sign in Indias next pharma gold rush is here and its not what you think
This could mean that we may see generics for popular drugs like semaglutide and tirzepatide in the future, further expanding treatment options for patients
Ethics statement The animal study was approved by Prof
The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, particularly through microdosing protocols, offers a promising therapeutic approach specifically tailored to address the unique metabolic challenges of this life stage